focus -WSS

focus

author：comprehensive 2025-10-02 20:48:47 - browse：34636

Blood corpuscles in clot — Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success. David Gregory & Debbie Marshall/Wellcome Images

Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success.

LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries. The tool is meant only for patients with a severe form of peripheral artery disease, and who have already tried more conservative options.

Dan Rose, CEO of LimFlow, previously told STAT that his mission is to fight the amputation epidemic in the United States, which disproportionately impacts Black patients. Experts cautioned to STAT that expanding screenings to catch the disease early is still the most important measure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Prior authorization will have to move faster under new Biden rule

entertainment

WSS

Elizabeth Holmes banned from government health programs

eGenesis tests gene

Air quality improving but still lags in Black, Hispanic communities

The drug industry has found itself all alone in Washington

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

eGenesis tests gene

leisure time

focus

entertainment

Drug repurposing or repositioning? The language matters

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Medical leaders decry Supreme Court decision on affirmative action

IVF, abortion rights issues kick off Biden’s State of the Union

Cancer drug shortages should be causing more outrage

Prior authorization will have to move faster under new Biden rule

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Francis Collins on trust in science and how Covid communications failed

State Dept. review finds Biden bears some blame for Afghanistan failures

The Readout: Amylyx, Alumis, and Lundbeck drug updates

entertainment

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

The drug industry has found itself all alone in Washington

Prior authorization will have to move faster under new Biden rule

Novo Nordisk obesity pill bests Wegovy in early trial

Why doctors need education on FDA device approval process

Why doctors need education on FDA device approval process

entertainment

focus

hotspot

explore